From Treatment To Prevention To A Cure: An Interview With Gilead’s HIV R&D Leaders

 
• By Joseph Haas

Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.

Gilead HQ
Gilead undertakes a host of R&D efforts to keep top position in HIV • Source: Shutterstock

More from Strategy

More from Business